Facilitated By

San Antonio Medical Foundation

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study To Assess The Efficacy And Safety Of Etrasimod In Subjects With Moderately To Severely Active Ulcerative C

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active

The primary objective of this study is to assess the efficacy of Etrasimod when administered for twelve (12) weeks on clinical remission in subjects with moderately to severely Active Ulcerative Colitis (UC).

Collaborative Project
Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.